Biotech Investors & VC Firms in Sydney
14 firms in this list, with a median first check of $1.8M. 8 of them lead rounds. Generated from verified public data and updated continuously.
Blackbird Ventures
SydneyPre-Seed–Series B$149K – $60M
51 people
Artesian
SydneyPre-Seed–Growth$20M
41 people
OneVentures
SydneySeed–Late Stage$3.3M – $13.2M
40 people
Antler Australia
SydneyPre-Seed–Series C$3M – $10M
17 people
Proto Axiom
SydneyPre-Seed–Seed
28 people
Crescent Capital Partners
SydneyGrowth–Late Stage$13.2M – $52.8M
24 people
Cicada Innovations
SydneySeed–Series A
18 people
Stoic VC
SydneyPre-Seed–Seed$65K – $650K
6 people
Jelix Ventures
SydneyPre-Seed–Series A
5 people
Alium Capital
SydneySeed–Late Stage
5 people
GrainCorp Ventures
SydneySeed–Series B$500K – $4M
1 person
East West Capital Limited
SydneySeed–Late Stage
1 person
UNSW
SydneyPre-Seed–Seed
CP Ventures
North SydneyPre-Seed–Series A$100K – $500K
3 people
Frequently asked questions
- Who are the top biotech investors & vc firms in sydney?
- Top biotech investors & vc firms in sydney include Blackbird Ventures, Artesian, OneVentures, Antler Australia, Proto Axiom, Crescent Capital Partners, Cicada Innovations, Stoic VC — 14 firms in total meet the criteria.
- What is the typical first check among biotech investors & vc firms in sydney?
- The median first check among the 14 biotech investors & vc firms in sydney tracked here is $1.8M.
- How many biotech investors & vc firms in sydney lead rounds?
- 8 of the 14 biotech investors & vc firms in sydney tracked here lead investment rounds.
Related lists
Investors & VC Firms in North America (12952)Investors & VC Firms in United States (11990)Investors & VC Firms in Europe (5859)Investors & VC Firms in Global (4787)AI & Machine Learning Investors & VC Firms (4629)Fintech Investors & VC Firms (4588)SaaS Investors & VC Firms (4239)Healthtech Investors & VC Firms (4227)Enterprise Software Investors & VC Firms (4136)Crypto & Web3 Investors & VC Firms (3986)
Data sourced from public filings and firms' own websites — see our methodology.


















































